Hengrui Medicine: 12 products adjusted in new national medical insurance catalog, 3 new drugs enter for first time

For a large-cap pharma like Hengrui, the significance lies less in the headline count than in the mix: first-time reimbursement for three new drugs and expanded indications for two innovative products are the levers that convert clinical pipelines into volume, while seven renewals suggest a maturing in-catalog base. The trade-off is familiar in China's NRDL process — broader access and lower patient costs typically come with price concessions, so the question is whether volume gains offset reimbursement-driven pricing. Watch how the new entrants and added indications translate into realized sales and whether further catalog rounds keep rewarding innovation over me-too portfolios.